

MSU 4.1-458
Appl. No. 09/513,086
October 11, 2005
Reply to Office action of July 11, 2005

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claims 1-3 (Cancelled).

4. (Currently Amended): A composition consisting of
~~comprising an isolated~~ a single naturally occurring 16 (+4)
kDa protein antigen isolated from Sarcocystis neurona
~~antigen and an isolated~~ a single naturally occurring 30 (+4)
kDa protein antigen isolated from Sarcocystis neurona
~~antigen~~ in a pharmaceutically accepted carrier.

Claims 5-12 (Cancelled).

13. (Currently Amended): A method for treating an equine with a *Sarcocystis neurona* infection comprising:

(a) providing a composition consisting ~~essentially of an isolated~~ of a single naturally occurring 16 (+4) kDa protein antigen isolated from *Sarcocystis neurona* and ~~an isolated~~ a single naturally occurring 30 (+4) kDa protein antigen isolated from ~~of~~ *Sarcocystis neurona* in a pharmaceutically accepted carrier; and

(b) inoculating the equine with the composition to treat the equine with the *Sarcocystis neurona* infection.

Claims 14-45. (Cancelled).

46. (Currently Amended): A method for treating a disease in an equine caused by a *Sarcocystis neurona* infection which comprises providing a composition which when injected into the equine causes the equine to produce antibodies against a 16 (\pm 4) kDa antigen and a 30 (\pm 4) kDa antigen of the *Sarcocystis neurona* which treats the disease caused by the *Sarcocystis neurona*, ~~The method of Claim 45~~ wherein the composition consists of ~~comprises an isolated a~~ single naturally occurring 16 (\pm 4) kDa protein antigen isolated from *Sarcocystis neurona* and an isolated a single naturally occurring 30 (\pm 4) kDa protein antigen isolated from *Sarcocystis neurona* in a pharmaceutically accepted carrier.

Claims 47-49 (Cancelled).

50. (Currently Amended): The method of Claim 46 ~~45~~ wherein the composition is administered by an inoculation route selected from the group consisting of intranasal administration, intramuscular injection, intraperitoneal injection, intradermal injection, and subcutaneous injection.